This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sebolt, J. S. Articles by Jackson, R. C. Search for Related Content PubMed PubMed Citation Articles by Sebolt, J. S. Articles by Jackson, R. C.

Pyrazoloacridines, a New Class of Anticancer Agents with Selectivity against Solid Tumors in Vitro

Chemotherapy Department, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105 [J. S. S., S. V. S., C. D. P., K. L. H., R. C. J.], and The Cancer Therapy and Research Center of South Texas and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284 [D. D. V. H.]

A series of 2-aminoalkyl-5-nitropyrazolo[3,4,5-kl]acridines (pyrazoloacridines) was evaluated in vitro for activity against a panel of human tumor cell lines of breast, colon, or lung origin. Several pyrazoloacridines were found to possess solid tumor selectivity relative to their activity against murine leukemia L1210 cells as well as human lymphoblastoid cells. The superior compounds in this regard were also found to exhibit excellent activity against primary human tumors in stem cell clonogenic assays. In addition, many of the compounds tested were found to be selectively cytotoxic to hypoxic relative to oxic HCT-8 colon adenocarcinoma cells, a property that may be a consequence of the potentially reducible 5-nitro function. A number of pyrazoloacridines were also found to exhibit potency against noncycling Chinese hamster ovary cells comparable to that observed against actively dividing cultures. Consistent with their favorable activity against nondividing cells, further testing of the pyrazoloacridines revealed that generally less drug is required to inhibit RNA synthesis than DNA synthesis in L1210 cells. Collectively these data indicate that the pyrazoloacridines represent a novel class of antitumor agents which warrant further preclinical evaluation for their potential clinical usefulness in the treatment of solid tumors.

¹ To whom requests for reprints should be addressed, at Chemotherapy Department, Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105.

Received 7/28/86. Revised 1/27/87. Revised 5/14/87. Accepted 5/19/87.

This article has been cited by other articles:

				J. Friedman, L. Nottingham, P. Duggal, F. G. Pernas, B. Yan, X. P. Yang, Z. Chen, and C. Van Waes Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6568 - 6578. [Abstract] [Full Text] [PDF]

				J. M. Reid, D. L. Walker, J. K. Miller, L. M. Benson, A. J. Tomlinson, S. Naylor, A. L. Blajeski, P. M. LoRusso, and M. M. Ames The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes Clin. Cancer Res., February 15, 2004; 10(4): 1471 - 1480. [Abstract] [Full Text] [PDF]

				Y. Hu, A. Krishan, W. Nie, K. S. Sridhar, L. D. Mayer, and M. Bally Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells Clin. Cancer Res., February 1, 2004; 10(3): 1160 - 1169. [Abstract] [Full Text] [PDF]

				N. Keshelava, D. Tsao-Wei, and C. P. Reynolds Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53 Clin. Cancer Res., August 1, 2003; 9(9): 3492 - 3502. [Abstract] [Full Text] [PDF]

				J. L. Grem, N. Harold, B. Keith, A. P. Chen, V. Kao, C. H. Takimoto, J. M. Hamilton, J. Pang, M. Pace, G. B. Jasser, et al. A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients Clin. Cancer Res., July 1, 2002; 8(7): 2149 - 2156. [Abstract] [Full Text] [PDF]

				K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann Flavopiridol Binds to Duplex DNA Cancer Res., May 1, 2000; 60(9): 2419 - 2428. [Abstract] [Full Text]